[Novel preclinical models and biomarkers for prostate cancer].

about

[Novel preclinical models and biomarkers for prostate cancer].

Item

http://www.wikidata.org/entity/Q44582971

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

[Novel preclinical models and biomarkers for prostate cancer].

@en

[Novel preclinical models and biomarkers for prostate cancer].

@nl

type

Item

label

[Novel preclinical models and biomarkers for prostate cancer].

@en

[Novel preclinical models and biomarkers for prostate cancer].

@nl

prefLabel

[Novel preclinical models and biomarkers for prostate cancer].

@en

[Novel preclinical models and biomarkers for prostate cancer].

@nl

P1476

[Novel preclinical models and biomarkers for prostate cancer]

@en

P2093

M Hohenfellner

http://www.w3.org/2001/XMLSchema#string

N Korzeniewski

http://www.w3.org/2001/XMLSchema#string

S Duensing

http://www.w3.org/2001/XMLSchema#string

S Pahernik

http://www.w3.org/2001/XMLSchema#string

Y Tolstov

http://www.w3.org/2001/XMLSchema#string

P2860

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Integrative genomic profiling of human prostate cancer

Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases.

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis

Punctuated evolution of prostate cancer genomes.

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

P304

1256-1260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00120-013-3310-6

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Boris Hadaschik

M A Tapia-Laliena

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255952327

http://www.w3.org/2001/XMLSchema#string

P698

23942741

http://www.w3.org/2001/XMLSchema#string

P921

biomarker